Research Reference
5-Amino-1MQ
NNMT inhibitor — metabolism and fat-loss research (oral)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor used for fat loss — taken orally in capsule form, not by injection. It is not a peptide in the traditional sense but is commonly grouped with research peptides in the metabolic optimization space.
No human clinical trials exist. All protocols are based on preclinical animal data and community experience.
Community protocol: 50 mg/day starting for 1–2 weeks, escalating to 100–150 mg/day. Cycle: 8–12 weeks on, 4–8 weeks off. Morning dosing, with or without food.
Side Effects & Safety
- Mild GI discomfort — most common, usually transient in the first week
- Slight stimulant effect — increased energy/alertness, especially early on
- Headaches — occasional, typically mild and dose-related
- Mild insomnia — if taken too late in the day
- No human clinical safety data — all safety information from preclinical studies and community reports
- No liver toxicity observed in animal studies at therapeutic doses
- Unknown drug interactions — theoretically could interact with NAD+-dependent pathways
Investigational research compound not approved by any regulatory body.
Research Basis
5-Amino-1MQ dosing is entirely community-derived, extrapolated from preclinical animal research. No human clinical trials have been conducted.
Key Preclinical Study (Neelakantan et al., 2018): Treatment in diet-induced obese mice produced progressive body weight loss, reduced white adipose tissue mass and adipocyte size, decreased total cholesterol, and no changes in food intake — effects were metabolic, not appetite-driven. The study used 20 mg/kg SC three times daily in mice.
NNMT as Target (Kraus et al., 2014): NNMT knockdown in white adipose tissue and liver protected against diet-induced obesity by increasing cellular energy expenditure. This established the mechanistic rationale for NNMT inhibition.
Combined Approaches (Neelakantan et al., 2022): NNMT inhibition with reduced-calorie diet produced dramatic adiposity reduction in DIO mice, normalizing metabolic parameters and establishing a distinct gut microbiome.
Community oral doses (50–150 mg daily) are based on allometric scaling from mouse studies, oral bioavailability data, and several years of community trial and error.